ANI Pharmaceuticals, Inc. announced the launch of its Prucalopride Tablets, a generic version of the drug Motegrity®, following final FDA approval of their Abbreviated New Drug Application. The new ...
1mon
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026 outlook.
The long-term thesis remains largely unchanged.
A new technique for 3D printing medication has enabled the printing of multiple drugs in a single tablet, paving the way for personalized pills that can deliver timed doses. Researchers from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results